Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Monash University |
---|---|
Information provided by: | Monash University |
ClinicalTrials.gov Identifier: | NCT00654966 |
Urotensin II (U-II) is newly discovered protein that may play an important role in human health and disease. U-II has been found to be a potent vasoconstrictor (narrower of blood vessels) which therefore may be involved in important diseases such as chronic heart failure - CHF (weak heart muscle disease). Many vasoconstrictors have been found to have effects on key organs such as the heart. Preliminary data by our group have demonstrated this is true of U-II. Recent evidence shows that in CHF, U-II levels in the blood are increased.
The proposed study seek to determine the effect of blocking U-II action on blood vessels by administration of a U-II antagonist (blocker). There will be 2 study groups 1) Healthy volunteers and, 2) CHF patients.
Each arm of the study will run independently and will require 16 participants each (16 normal subjects and 16 CHF subjects). Participants will be screened to ensure that they are eligible. CHF patients will be required to withdraw from their CHF medication 24 hours prior to the study day (except for diuretics). On the study day, U-II antagonist will be administered on the skin of participants in various settings. The technique to be used is iontophoresis. This is a non invasive technique in which a small amount of the compound is placed on the skin of the forearm. The drug is delivered across the skin by passing a small electric current over the area. The change in blood flow is then measured and analyzed. We will also administer U-II itself, noradrenaline, and distilled water. Noradrenaline will be used a positive constrictor control. If it is found that U-II blocker is able to prevent blood vessel constriction in CHF patients, then it may represent a major therapeutic advance in the management of CHF.
Condition | Intervention | Phase |
---|---|---|
Heart Failure |
Drug: Urotensine II Drug: ENC8003 (Urotensin II antagonist) |
Phase II |
Study Type: | Interventional |
Study Design: | Basic Science, Open Label, Active Control, Parallel Assignment |
Official Title: | Evaluation of the Effects of Urotensin-II and Urotensin-II Antagonist on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers. |
Enrollment: | 0 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | June 2010 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Heart failure patients
|
Drug: Urotensine II
A few drops of the drug will be administered to the skin by iontophoresis.
Drug: ENC8003 (Urotensin II antagonist)
A few drops of the drug will be administered to the skin by iontophoresis.
|
2: Active Comparator
Healthy subjects
|
Drug: Urotensine II
A few drops of the drug will be administered to the skin by iontophoresis.
Drug: ENC8003 (Urotensin II antagonist)
A few drops of the drug will be administered to the skin by iontophoresis.
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Australia, Victoria | |
Alfred Hospital | |
Melbourne, Victoria, Australia, 3004 |
Principal Investigator: | Henry Krum, MBBS FRACP PhD | Monash University / Alfred Hospital |
Responsible Party: | Monash University / Alfred Hospital ( Prof Henry Krum ) |
Study ID Numbers: | CP-02/08, 77/08 |
Study First Received: | April 3, 2008 |
Last Updated: | October 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00654966 History of Changes |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
Urotensin II Urotensin II antagonist Iontophoresis Healthy volunteers |
Heart Failure Heart Diseases Healthy |
Heart Failure Heart Diseases Cardiovascular Diseases |